Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases.

ABSTRACT: Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors. HCLv is characterized by unfavorable prognosis, low complete remission rates and limited disease control following classical hairy cell leukemia-based regimens. In this study, we report 3 cases of elderly patients with treatment-naive, TP53 un-mutated HCLv, who were effectively treated with four cycles of bendamustine plus rituximab. The regimen was completed in all the patients with acceptable toxicity. All patients achieved a complete clinical response with no evidence of residual disease at bone marrow biopsy and flow-cytometry examination. After a median follow-up of 19 months, the 3 subjects are still in complete remi

SUBMITTER: Visentin A 

PROVIDER: S-EPMC5746417 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature